CN Patent

CN113278013B — 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用

Assigned to Shanghai Kunheng Medical Technology Co ltd · Expires 2022-09-23 · 4y expired

What this patent protects

本发明提供了一种2,6‑二取代的1,2,4‑三嗪‑3,5‑二酮化合物，具有式Ⅰ所示结构，或其药学上可接受的盐。上述三嗪酮衍生物结构新颖且显示出优良的THRβ激动作用，能够作为甲状腺激素受体相关疾病的治疗和/或预防药物来发挥作用。

USPTO Abstract

本发明提供了一种2,6‑二取代的1,2,4‑三嗪‑3,5‑二酮化合物，具有式Ⅰ所示结构，或其药学上可接受的盐。上述三嗪酮衍生物结构新颖且显示出优良的THRβ激动作用，能够作为甲状腺激素受体相关疾病的治疗和/或预防药物来发挥作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN113278013B
Jurisdiction
CN
Classification
—
Expires
2022-09-23
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Kunheng Medical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.